Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

112
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
112
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

146
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
146
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

39
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
39
Phase II Reactions: Glucuronidation01:24

Phase II Reactions: Glucuronidation

294
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
294
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry01:20

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

177
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
177
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

3.7K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Method Development and Validation of Liquid Chromatography Tandem Mass Spectrometry for SLP-1A6 in Rat Plasma.

Journal of chromatographic science·2026
Same author

Preclinical Development of GT-14, a Novel Inhibitor of Gα<sub>i</sub>2 Protein: Comprehensive Evaluation of Physicochemical, Metabolic Characteristics and Tissue Distribution.

The AAPS journal·2025
Same author

Development and validation of a novel LC-MS/MS method for simultaneous quantification of alvocidib and its glucuronide: application to pharmacokinetic and tissue distribution study in rats.

Analytical methods : advancing methods and applications·2025
Same author

Drug Metabolism and Pharmacokinetic Evaluation of a Novel RNase H2 Inhibitor for the Treatment of Triple-Negative Breast Cancer.

Pharmaceutics·2025
Same author

Clay Attenuates Diarrhea Induced by Fat in a Mouse Model.

Metabolites·2025
Same author

An LC-MS Method to Quantify Rhein and Its Metabolites in Plasma: Application to a Pharmacokinetic Study in Rats.

Metabolites·2025
Same journal

Lactate Metabolism Dysregulation Drives the Pathogenesis of Acute Kidney Injury.

Metabolites·2026
Same journal

Librarian: An Open-Access Web Application for High-Resolution Mass Spectral Library Assembly.

Metabolites·2026
Same journal

Purine Metabolism Alterations in Patients with Chronic Heart Failure: A Cross-Sectional Study of Associations with Iron Status, Oxidative Stress, and Anemia.

Metabolites·2026
Same journal

The Gut Microbiome in Heart Failure: Pathways to Inflammation and Therapeutic Targets.

Metabolites·2026
Same journal

Metabolic Mechanisms of Hexavalent Chromium-Induced Splenic Immune Injury via Oxidative Stress and Ferroptosis Pathways in New Zealand Rabbits.

Metabolites·2026
Same journal

Improving Speed and Efficiency of DESI Imaging with the Xevo MRT Mass Spectrometer for Analyte Mapping.

Metabolites·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

Species Differences in Ezetimibe Glucuronidation.

Shalom Emmanuel1, Eric A Asare1, Ting Du1

  • 1Department of Pharmaceutical Science, College of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.

Metabolites
|November 26, 2024
PubMed
Summary
This summary is machine-generated.

Species differences in ezetimibe glucuronidation rates were observed, impacting its metabolism. These variations are crucial for accurate pharmacokinetic and toxicological assessments of ezetimibe across different models.

Keywords:
UGTezetimibeglucuronidationspecies differences

More Related Videos

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.8K
Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota
13:35

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Published on: May 23, 2025

191

Related Experiment Videos

Last Updated: Jun 6, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.8K
Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota
13:35

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Published on: May 23, 2025

191

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Biochemistry

Background:

  • Ezetimibe, a cholesterol-absorption inhibitor, is extensively metabolized to ezetimibe glucuronide.
  • Species differences in metabolism are critical for accurate pharmacokinetic and pharmacodynamic evaluations.
  • Understanding ezetimibe glucuronidation variability is essential for drug development and safety assessment.

Purpose of the Study:

  • To compare species differences in ezetimibe glucuronidation rates.
  • To investigate ezetimibe glucuronidation using intestinal microsomes from humans, rats, mice, monkeys, and dogs.

Main Methods:

  • Intestinal microsomes from multiple species were utilized.
  • Ezetimibe glucuronidation rates were assessed at various substrate concentrations (0.5–50 µM).
  • Enzyme kinetic parameters were determined using the Michaelis-Menten model.

Main Results:

  • Significant differences in ezetimibe glucuronidation rates were found among species.
  • Monkey intestinal microsomes exhibited the highest Vmax, followed by rat, mouse, human, and dog.
  • Intra-species clearance (CLint) showed an 8.17-fold variation, with mouse > dog > human > rat = monkey.

Conclusions:

  • Species-specific differences in intestinal ezetimibe glucuronidation rates significantly impact drug metabolism.
  • These variations must be considered when analyzing ezetimibe pharmacokinetics, pharmacodynamics, and toxicology.
  • Accurate interpretation of ezetimibe studies requires accounting for inter-species metabolic differences.